SWOG clinical trial number
S1900K

A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

18% Accrual
Accrual
18%
Open
Phase
18% Accrual
Accrual
18%
Abbreviated Title
Targeted Treatment for Advanced NSCLC that has a MET Exon 14 Skipping Gene Change
Status Notes
S1900K will open to accrual December 18, 2023, effective 3:00 p.m. EST.
Activated
12/18/2023
Participants
US INSTITUTIONS ONLY

Research committees

LungMAP

Treatment

Ramucirumab Tepotinib

Reports & Approvals

Trial Locations